FDA Jeopardizes the Lives of Lung Transplant Recipients and in the Process Severely Increases the Cost to Develop New Immunosuppression

American Journal of Transplantation - United Kingdom
doi 10.1111/ajt.15215
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley


Related search